Trial Profile
Patient survival, disease recurrence and tumour pathology following preoperative treatment with anti-oestrogen therapies using a single dose of Faslodex [fulvestrant] or tamoxifen therapy in postmenopausal women prior to surgery for primary breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 May 2006
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 15 May 2006 New trial record.